Cornerstone Wealth Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.79M | Sell |
5,213
-125
| -2% | -$127K | 0.24% | 100 |
|
|
2025
Q4 | $5.74M | Sell |
5,338
-10
| -0.2% | -$9.56K | 0.3% | 81 |
|
|
2025
Q3 | $4.08M | Buy |
5,348
+1,009
| +23% | +$751K | 0.23% | 102 |
|
|
2025
Q2 | $3.38M | Buy |
4,339
+197
| +5% | +$153K | 0.21% | 106 |
|
|
2025
Q1 | $3.42M | Buy |
4,142
+319
| +8% | +$265K | 0.23% | 101 |
|
|
2024
Q4 | $2.95M | Buy |
3,823
+405
| +12% | +$335K | 0.2% | 106 |
|
|
2024
Q3 | $3.03M | Buy |
3,418
+1,531
| +81% | +$1.38M | 0.21% | 100 |
|
|
2024
Q2 | $1.71M | Buy |
1,887
+294
| +18% | +$235K | 0.13% | 146 |
|
|
2024
Q1 | $1.24M | Sell |
1,593
-241
| -13% | -$172K | 0.1% | 175 |
|
|
2023
Q4 | $1.07M | Buy |
1,834
+56
| +3% | +$32.7K | 0.09% | 185 |
|
|
2023
Q3 | $955K | Buy |
1,778
+31
| +2% | +$16K | 0.09% | 189 |
|
|
2023
Q2 | $819K | Sell |
1,747
-480
| -22% | -$201K | 0.07% | 214 |
|
|
2023
Q1 | $765K | Buy |
+2,227
| New | +$751K | 0.08% | 215 |
|
|
2022
Q3 | $751K | Buy |
2,322
+186
| +9% | +$58.9K | 0.08% | 193 |
|
|
2022
Q2 | $693K | Sell |
2,136
-252
| -11% | -$75.6K | 0.08% | 207 |
|
|
2022
Q1 | $684K | Sell |
2,388
-89
| -4% | -$22.9K | 0.07% | 227 |
|
|
2021
Q4 | $685K | Buy |
2,477
+290
| +13% | +$73.5K | 0.07% | 240 |
|
|
2021
Q3 | $505K | Sell |
2,187
-101
| -4% | -$24.9K | 0.05% | 273 |
|
|
2021
Q2 | $525K | Buy |
2,288
+67
| +3% | +$13.5K | 0.06% | 274 |
|
|
2021
Q1 | $415K | Buy |
2,221
+203
| +10% | +$39.7K | 0.05% | 295 |
|
|
2020
Q4 | $341K | Buy |
2,018
+147
| +8% | +$21.9K | 0.04% | 311 |
|
|
2020
Q3 | $277K | Sell |
1,871
-147
| -7% | -$22.8K | 0.04% | 322 |
|
|
2020
Q2 | $331K | Buy |
2,018
+37
| +2% | +$5.68K | 0.05% | 267 |
|
|
2020
Q1 | $275K | Buy |
1,981
+1
| +0.1% | +$137 | 0.05% | 274 |
|
|
2019
Q4 | $260K | Sell |
1,980
-493
| -20% | -$57.1K | 0.04% | 292 |
|
|
2019
Q3 | $277K | Buy |
2,473
+2
| +0.1% | +$223 | 0.05% | 276 |
|
|
2019
Q2 | $274K | Buy |
2,471
+124
| +5% | +$14.6K | 0.05% | 295 |
|
|
2019
Q1 | $642K | Buy |
2,347
+139
| +6% | +$16.9K | 0.08% | 245 |
|
|
2018
Q4 | $255K | Sell |
2,208
-332,774
| -99% | -$37.2M | 0.05% | 281 |
|
|
2018
Q3 | $3.85M | Buy |
334,982
+105,365
| +46% | +$10.5M | 0.05% | 351 |
|
|
2018
Q2 | $2.67M | Buy |
229,617
+226,814
| +8,092% | +$18.6M | 0.03% | 450 |
|
|
2018
Q1 | $211K | Buy |
2,803
+37
| +1% | +$2.98K | 0.04% | 352 |
|
|
2017
Q4 | $238K | Sell |
2,766
-1,082
| -28% | -$92.1K | 0.04% | 348 |
|
|
2017
Q3 | $337K | Sell |
3,848
-590
| -13% | -$48.4K | 0.07% | 268 |
|
|
2017
Q2 | $362K | Buy |
4,438
+56
| +1% | +$4.57K | 0.08% | 236 |
|
|
2017
Q1 | $376K | Sell |
4,382
-174
| -4% | -$13.9K | 0.09% | 219 |
|
|
2016
Q4 | $340K | Buy |
4,556
+602
| +15% | +$44.8K | 0.11% | 177 |
|
|
2016
Q3 | $320K | Buy |
+3,954
| New | +$316K | 0.12% | 169 |
|
Other funds holding LLY
VCM
VPM
Cornerstone Wealth Management's LLY Position: Q1 2026 in Review
Cornerstone Wealth Management reduced its Eli Lilly (LLY) stake by 2.3% in Q1 2026, selling an estimated $127K and leaving 5,213 shares worth $4.79M. The position accounts for 0.24% of the portfolio, ranked #100.
Cornerstone Wealth Management first reported a position in LLY in Q3 2016 and has held it in 38 quarters since. The position peaked at $5.74M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Cornerstone Wealth Management held 5,213 shares of Eli Lilly worth $4.79M as of Q1 2026.
- Cornerstone Wealth Management sold 125 Eli Lilly shares in Q1 2026, an estimated $127K.
- Eli Lilly made up 0.24% of Cornerstone Wealth Management's portfolio in Q1 2026, its #100 holding.
- Cornerstone Wealth Management first reported a position in Eli Lilly in Q3 2016 and has held it in 38 quarters since.
- Cornerstone Wealth Management's Eli Lilly position peaked at $5.74M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Cornerstone Wealth Management's 13F filing for Q1 2026, filed 24 Apr 2026.